Day One
8:00 am Chair’s Opening Remarks
An Update From the Field – Where Are We Now & What Lies Ahead?
8:10 am An Overview of the 2021 WHO Classification and Implications for Diffuse Glioma Diagnosis
Synopsis
- Major conceptual changes in the 2021 WHO classification of CNS tumors
- Major specific changes in the 2021 WHO criteria for diffuse glioma diagnosis
8:40 am Impact of Molecular Classification of GBM on Clinical Trial Design and Analysis
Synopsis
- Review of the molecular classification of GBM
- Impact on clinical trial design
- Impact on clinical trial analysis
9:10 am Why Are We Not Doing Better? Overview Of Limitations of Current Drug Development for GBM and Potential Improvements
Synopsis
- Overview of drug development for GBM
- Discussion of pitfalls and mistakes
- Potential solutions
9:25 am Panel: Why Are We Not Doing Better? An Open Discussion of the Limitations of Current Drug Development for GBM and Where the Field Can Improve
Synopsis
- Barriers to advancing drug development and strategies to address these
- Major therapeutic strategies currently under development
- How can drug developers cut to the real barriers, and debate what is truly required to break through to successful treatments for GBM?
10:00 am Keeping the Passion Going, Harnessing the Passion of a Dynamic Founder
Synopsis
- Key lessons learned in OurBrainBank’s leadership transition from Founder to CEO
- The future of patient power – how Jessica Morris’ founding vision for patient engagement is reflected in OBB’s 2022-24 organizational strategy
10:15 am Morning Break & Speed Networking
Cancer Metabolism & The Tumor Micro-Environment
11:15 am Presentation Slot Reserved for Medicenna
Synopsis
11:45 am Accounting for Cancer on the Spectrum in Drug Development
Synopsis
- Appreciate the distinction between sex differences and sexual dimorphism
- Understanding the utility of Bayesian Nearest Neighbor Analyses in this endeavor
- Recognize the importance of incorporating sex differences in drug
development
12:15 pm Sex Differences in the GBM Immune Response
Synopsis
- There are key sex differences in the myeloid compartment in both mouse GBM models and human GBM patients
- The male tumor microenvironment contains myeloid cells while female
immune suppression is systemically regulated - These sex differences in immune suppression can be leveraged for
precision medicine based therapeutic strategies
12:45 pm Developmental Pathways, Plasticity and Neural Regulation of Pediatric High-Grade Glioma
Synopsis
- The architecture of pediatric high-grade gliomas resembles normal
development - Histone 3 mutant gliomas (K27M and G34R/V) have distinct developmental origins
- Intra-tumoral hierarchy and plasticity is tumor-type specific
- Targeting lineage specific cancer cell states represents new treatment
approach
1:15 pm Lunch & Networking
Optimizing Clinical Trial Design to Drive Forward Drug Development
2:15 pm Role of Cytotoxic Agents in GBM
Synopsis
- GBM Treatment Challenges
- History of VAL-083
- Unique Mechanism of Action of VAL-083
- VAL-083 Treatment Arm in the GCAR GBM AGILE Study
2:45 pm Leveraging External Data for the Design and Analysis of Glioblastoma Trials
Synopsis
- Discuss sources of external data and challenges to data access and data-sharing
- Design & evaluate the use of real world evidence and clinical trial data to develop external control arms in GBM
- Assess the utility of external data, including real world data and clinical trial data to increase efficiency of clinical trials in GBM
3:15 pm Presentation Details to be confirmed
3:45 pm Afternoon Break & Refreshments
4:15 pm RANO. 2.0 Update in Response Assessment for Glioblastomas
Synopsis
- Outline current limitations of RANO criteria
- Data comparing RANO, mRANO and iRANO
- Proposed updates to the RANO criteria
4:45 pm AV-GBM-1 Patient-Specific Vaccines in Newly Diagnosed Primary Glioblastoma
Synopsis
- AV-GBM-1 product and manufacturing feasibility update
- Phase 2 safety and survival data including exploratory subset analyses
- Phase 3 clinical trial considerations and design
Developing Effective Vaccines for Treatment of GBM
5:15 pm Oral DNA Vaccination in Combination With Checkpoint Inhibitor In Recurrent Glioblastoma
Synopsis
- Cytotoxic T-cell approach targeting VEGFR-2 on tumor vasculature and tumor cells
- Combination with checkpoint inhibitors
- Intratumoral immune-biomarkers pre- and post treatment